BioCentury
ARTICLE | Product Development

Next-generation checkpoint development surges as rare wins overshadow setbacks

Companies look to overcome challenges in next-generation checkpoints with new targets and modalities

March 26, 2021 12:51 AM UTC

Though the failure rate of next-generation checkpoints has far out-stripped that of the rare successes, companies have not been scared away from the search for the next blockbuster, or for a way to finally cut back checkpoint resistance.

New additions to the checkpoint pipeline have outpaced terminations as the number of programs against next-generation T cell checkpoints expands each year. The candidate collection is also beginning to look much more diverse as companies turn to new targets, new mechanisms and new modalities in the search for a safe and effective agent...